Glaukos Corp posted second‑quarter net sales of $185.6 million, a 50% increase year‑over‑year, while EPS came in at $‑0.14 versus a $‑0.23 consensus. The surge in sales and improved earnings outlook broaden the company’s growth runway and justify the stock’s near‑double rally this year.

Key Highlights

  • Net sales hit $185.6 million in Q2, up 50% YoY and 49% on a constant‑currency basis.
  • GAAP gross margin expanded to roughly 82%, with non‑GAAP margin reaching about 85%.
  • FY 2026 revenue guidance lifted to $680 million‑$700 million, up from the prior $620 million‑$635 million range.
  • Shares rallied strongly after the release, reflecting investor confidence in the upgraded outlook.

Glaukos Corp (NYSE: GKOS) disclosed that second‑quarter net revenue reached $185.6 million, a 50% increase compared with the same period a year earlier. Adjusted earnings per share were $‑0.14, surpassing analyst expectations. The company also raised its full‑year sales projection to a range of $680 million to $700 million, underscoring confidence in its expanding product portfolio.

EPS Beats Consensus

The reported EPS of $‑0.14 exceeded the consensus forecast, indicating improved cost efficiency and higher contribution from newly launched therapies. GAAP gross margin improved to approximately 82%, while the non‑GAAP margin climbed to near 85%, both reflecting better pricing dynamics and operational execution. Expenses related to selling, general and administrative functions, as well as research and development, grew in line with the company’s strategic investments, but the overall operating loss narrowed versus the prior year, signaling a positive trajectory toward profitability.

Sales Surge 50% YoY

Quarterly revenue was driven largely by the glaucoma franchise, delivering record net sales of $155.2 million. Within this segment, U.S. glaucoma sales amounted to $118.5 million, illustrating strong domestic demand.

International contributions added meaningful growth, while the corneal health portfolio also experienced strong momentum, reinforcing the company’s diversified revenue base.

Market Reaction and Peer Context

Following the earnings release, Glaukos’s share price moved higher, mirroring the market’s positive reaction to the upgraded guidance and expanding product reach. The stock’s performance outpaced many peers in the ophthalmic sector, highlighting investor optimism about Glaukos’s growth prospects. While elevated spending on sales and research activities suggests ongoing cash utilization, the company’s cash position remains healthy, supporting its continued investment in pipeline development.

Forward Guidance and Upcoming Catalyst

Management’s outlook now targets full‑year sales between $680 million and $700 million, a step up from the previously disclosed $620 million‑$635 million band. This outlook is anchored in anticipated acceleration of iDose TR adoption, broader international penetration, and the scaling of the newly launched corneal therapy. Looking ahead, a key event will be the implementation of a proposed Centers for Medicare & Medicaid Services (CMS) rule for calendar year 2027, slated for July 1, 2027, which could affect reimbursement structures for glaucoma procedures and influence the company’s long‑term profitability.

Peers Moving on This News

  • Baxter International Inc (BAX) up 1.1%
  • Penumbra Inc (PEN) little changed
  • Insulet Corp (PODD) up 2.5%

Analysis based on the Form 8-K filed 29 July 2026; figures verified against the filing and live market data.

This article is for informational purposes only and does not constitute financial advice. Please consult a licensed financial adviser before making investment decisions.